Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024 - Siouxland News - KMEG 14 and FOX 44

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, June 18 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

http://www.reportlinker.com/p02148732/Vaccine-Manufacturing-Technology-and-Services-World-Market-Forecast-2014-2024.html

Prospects For Leading Players

Report Details

Vaccine manufacturing technology and services - your guide to trends and revenue prospects for vaccine production

What's the outlook for producing vaccines? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 205 page report provides 104 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2014 to 2024, with growing revenues.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of four exclusive expert opinion interviews from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Eluemuno Blyden, CEO and Founder, AfriVax
- Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
- Dr. Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
- Dr. Stefan Beyer, Managing Director, Vibalogics

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting for these five world-level vaccine submarkets to 2024:
- Paediatric vaccines
- Influenza vaccines
- Adult prophylactic vaccines
- Therapeutic vaccines
- Contract vaccine manufacturing

Our investigation shows business research and analysis with individual revenue forecasts and discussions. Which vaccine submarket will generate the most revenues? How will the vaccine contract manufacturing market expand? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

What are the prospects for vaccine contract manufacturing in the leading regions and countries?

Events and progress worldwide will influence the market, especially outsourced vaccine manufacturing in emerging countries.

In our study you will find individual revenue forecasts to 2024 for 11 vaccine contract manufacturing national markets:
- US
- Japan
- Germany
- Italy
- Spain
- France
- UK
- Russia
- China
- India
- Brazil
- RoW

Many opportunities exist within the vaccines contract manufacturing market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Leading companies and potential for market growth

Overall world revenue for the vaccines contract manufacturing market will reach $705.62m in 2014, our study forecasts. We predict strong revenue growth from 2014 to 2024. Our research shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
- Baxter BioPharma Solutions
- Boehringer Ingelheim
- Catalent
- Charles River Laboratories
- IDT Biologika GmbH
- Lonza
- Meridian Life Science
- Sigma-Aldrich
- SynCo Bio Partners
- OSO BioPharmaceuticals Manufacturing

In general, a company profile gives you the following information:
- Overview of the company
- Discussion of a company's activities and outlook including descriptions of leading products
- Recent financial results
- Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures

What issues will affect the vaccine contract manufacturing market?

Our new report discusses issues and events affecting the vaccine contract manufacturing market. You will find discussions, including qualitative analyses:
- Healthy pipeline of vaccine products
- Cell-based techniques - mammalian cell lines, avian-derived cells, plant-based processes and other methods
- Pandemic preparedness
- Pricing, regulation and government policy
- Perception of risk in outsourcing vaccine manufacturing

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024: Prospects For Leading Players report helps you

In summary, our 205 page report gives you the following knowledge:
- Revenues forecasts to 2024 for the overall world vaccine market and 5 submarkets - discover the industry's prospects, finding promising places for investments and revenues
- Assessment of 10 leading companies, and others, discovering their activities and outlooks
- Market forecasting to 2024 for 11 leading national vaccine contract manufacturing markets - USA, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India, China and RoW
- View opinions from our survey, seeing 4 interviews with leading authorities
- Investigation of competition and opportunities influencing sales
- Discussion of what stimulates and restrains the vaccine contract manufacturing market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how our report could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.
1. Executive Summary

1.1 Overview
1.2 Review of the Vaccine Manufacturing Technology and Services Market
1.3 Aims, Scope and Format of Report
1.4 Research and Analysis Methods

2. Introduction to the Vaccine Market

2.1 What Are Vaccines?
2.2 The History of the Vaccine Market
2.3 The Vaccine Contract Manufacturing Market
2.3.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
2.3.2 Reasons to Outsource
2.3.3 Benefits of Outsourcing
2.3.4 The Challenges in Outsourcing Vaccine Manufacturing
2.3.5 Why Should Companies Outsource Vaccine Manufacturing?
2.3.6 Strategic Outsourcing vs. Tactical Outsourcing
2.3.7 Virtual Companies
2.3.8 Contract Manufacturing Organisations (CMOs)
2.3.9 Manufacturing Services Offered by CMOs
2.3.10 Vaccine Manufacturing Activities Typically Outsourced

3. Vaccine Manufacturing Technologies 2014

3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift Towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago's Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax's Sf9/BV Technology
3.2.6.2 Protein Sciences Corporation (PSC): First Egg-Free Influenza Vaccine
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors

3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Leading Pre-Filled Vaccine Products 2014
3.5.3 Drivers and Restraints for Pre-filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges with Some Flu Vaccine
3.5.4.3 Novartis' Agriflu and Fluad Ban is Lifted
3.5.4.4 Baxter Flu Vaccine and Side Effects
3.5.4.5 Reported Shelf Life Issues of Some H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.7 Cell Media Can Improve Virus Yield

4. The Vaccine Market 2014-2024

4.1 The Global Vaccine Market, 2014-2024
4.2 The Global Vaccine Market By Submarket, 2012 and 2013
4.3 The Global Vaccine Market by Submarket, 2014-2024
4.4 The Paediatric Vaccine Submarket Forecast, 2014-2024
4.4.1 Growth of Paediatrics Vaccines is Driven by Prevnar's Blockbuster Success
4.4.2 Paediatric Vaccines: The Biggest Segment, but the Least Dynamic
4.4.3 Paediatric Vaccine Pipeline
4.5 The Adult Prophylactic Vaccine Submarket Forecast, 2014-2024
4.5.1 Adult Vaccination: Low Uptake
4.5.2 Gardasil Represented Nearly a Fifth of Segment Revenues in 2012
4.5.3 Adult Prophylactic Vaccines: Extensive Pipeline, but Still Needs to Become More Widely Established
4.5.4 Adult Prophylactic Vaccine Pipeline
4.6 The Influenza Vaccine Submarket, 2014-2024
4.6.1 Influenza: Growth is Driven by Seasonal Epidemics and Global Pandemics
4.6.2 Significant Scope for Enlarging the Patient Population
4.6.3 Influenza Market: High Innovation, Low Market-Entry Barriers, High Volumes of Product Needed
4.6.4 Influenza Product Pipeline
4.7 The Therapeutic Vaccine Submarket, 2014-2024
4.7.1 Therapeutic Vaccines: the Holy Grail of Personalised Vaccines
4.7.2 Therapeutic Vaccines: On the Cusp of an Explosion or Another Vaccine Hype?
4.7.2.1 Underperformance: Provenge is the First and Only FDA Approved Cancer Vaccine
4.7.2.3 Biovac ID Completes Phase III for Cancer Vaccine
4.7.3 Anti-Allergy Vaccines Make Up Bulk of Segment in 2013
4.7.3.1 Canada Gives Merck & Co. Its First Approval for Grass Allergy Vaccine Tablet
4.7.3.2 Therapeutic Vaccine Product Pipeline

5. The Global Vaccine Contract Manufacturing Market 2014-2024

5.1 Global Vaccine Contract Manufacturing: A Tiny Fraction of The Total Vaccine Market
5.2 The Vaccine Contract Manufacturing Market Forecast: High Growth Rates from 2014-2024
5.2.1 Trends in the Vaccine Contract Manufacturing Forecast
5.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.3.1 The Leading National Markets for Vaccine Contract Manufacturing: Largely Dictated by the Local Vaccine Market
5.3.2 The Leading National Markets for Vaccine Contract Manufacturing, 2012 and 2013
5.3.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.4 The US Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5 The Japanese Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5.1 CMO's in Japan
5.6 The EU5 Vaccine Contract Manufacturing Market, 2012 and 2013
5.6.1 The EU5 Vaccine Contract Manufacturing Market, 2014-2024
5.6.2 The French Vaccine Contract Manufacturing Market, 2014-2024
5.6.3 The German Vaccine Contract Manufacturing Market, 2014-2024
5.6.4 The Italian Vaccine Contract Manufacturing Market, 2014-2024
5.6.5 The Spanish Vaccine Contract Manufacturing Market, 2014-2024
5.6.6 The UK Vaccine Contract Manufacturing Market, 2014-2024
5.7 The Brazilian Vaccine Contract Manufacturing Market, 2014-2024
5.8 The Russian Vaccine Contract Manufacturing Market, 2014-2024
5.9 The Indian Vaccine Contract Manufacturing Market, 2014-2024
5.10 The Chinese Vaccine Contract Manufacturing Market, 2014-2024
5.10.1 Vaccine Manufacturing: Questioning China's Regulatory Standards

6. The Leading Vaccine Contract Manufacturing Companies 2014-2024

6.1 The Vaccine Contract Manufacturing Market has Room for Consolidation
6.2 Baxter BioPharma Solutions
6.2.1 Business Capabilities
6.3 Boehringer Ingelheim
6.3.1 Recent Financial Performance
6.3.2 Boehringer Ingelheim's Ben Venue Closure
6.3.3 Manufacturing Deals 2011-2014
6.3.4 Boehringer Ingelheim Implements Fully Disposable Biopharmaceutical Manufacturing
6.3.5 Boehringer Ingelheim Expands Biopharmaceuticals in China
6.3.6 Outlook
6.4 Catalent
6.4.1 Recent Financial Performance, 2008-2012
6.4.2 Recent Financial Performance by Segment, 2008-2012
6.4.3 Catalent Injectable Vaccines
6.4.4 Catalent Adjusts its Services
6.4.5 Future Strategies for Growth
6.4.6 Regional Market Expansion
6.5 Charles River Laboratories
6.5.1 Recent Financial Performance, 2008-2012
6.5.2 Recent Financial Performance, 3Q 2013

6.5.3 Recent Financial Performance by Segment
6.5.4 Vaccine Manufacturing Services
6.5.4.1 Vaccine Manufacturing Expansion
6.5.5 Future Outlook and Early Stage Restructuring
6.5.6 Partnerships
6.5.6.1 Partnership with AstraZeneca
6.5.6.2 Partnership with Batavia
6.6 IDT Biologika GmbH
6.6.1 Facility Expansion
6.6.2 Acquisitions and Partnerships
6.6.2.1 Acquisition of Riemser Pharma GmbH
6.6.2.2 Partnership with ImVisioN Therapeutics
6.7 Lonza
6.7.1 Recent Financial Performance, 2010-2012
6.7.1.1 Recent Financial Performance by Segment,2012
6.7.2 Manufacturing Division Restructuring
6.8 Meridian Life Science
6.8.1 Recent Financial Performance, 2008-2013
6.8.1.1 Recent Financial Performance by Segment, 2008-2013
6.8.1.2 Recent Financial Performance by Region, 2012-2013

6.9 Sigma-Aldrich
6.9.1 Revenue and Recent Performance Analysis, 2010-2013
6.9.1.1 Recent Financial Performance by Segment, 2010-2012
6.9.1.2 Segment restructuring, 2013
6.9.2 Strategy for Business Growth by Asian Expansion
6.9.3 Acquisition of BioReliance
6.9.4 Partnership with CatScl
6.10 SynCo Bio Partners
6.10.1 Recent Developments
6.10.1.1 Expansion of Facilities
6.10.1.2 FDA Approval of Partner Application
6.11 OSO BioPharmaceuticals Manufacturing
6.11.1 Facilities and Capabilities
6.11.2 New Developments
6.11.2.1 Acquisition of Catalent's Sterile Injectables Manufacturing Business
6.11.2.2 Facility Investment
6.12 Leading Vaccine Contract Manufacturing Organisations

7. SWOT Analysis of the Vaccine Contract Manufacturing Market 2014-2024

7.1 Vaccine Contract Manufacturing Industry Trends
7.2 Strengths
7.2.1 Many Companies Cannot Afford In-house Capabilities
7.2.2 Outsourcing Improves Time to Market
7.2.3 Manufacturers get Access to Specialised Technologies
7.2.4 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
7.3 Weaknesses
7.3.1 Mass Vaccine Manufacturing is Kept In-house
7.3.2 A Highly Fragmented Vaccine Contract Manufacturing Market
7.3.3 An Unpredictable Supply and Demand Business Model
7.3.4 Lack of Differentiation in the CMO Space
7.4 Opportunities
7.4.1 Many Vaccines in the Product Pipeline
7.4.2 Therapeutic Vaccine Market could Explode
7.4.3 Emerging Market's Growing Demand for Vaccines
7.4.3.1 Dynamic Change: Emerging Markets are Major Vaccine Developers
7.5 Threats
7.5.1 Post Recession: Biotech Suffer from Severe Cuts in Capitalist Funding
7.5.2 The Public are Slow to Accept Novel Technologies
7.5.3 Perception of Risk by the Original Vaccine Manufacturers

8. Expert Opinion

8.1 Interview with Dr. Eluemuno Blyden, CEO and Founder, AfriVax
8.1.1 The Egg-based Vaccine Manufacturing Myth
8.1.2 AfriVax's New Vaccine Manufacturing Technology
8.1.3 Emerging Markets Pathing their Own Vaccine Path
8.2 Interview with Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
8.2.1 Growth of the Vaccine Contract Manufacturing Market
8.2.2 The Therapeutic Vaccine Market
8.2.3 The Use of Emerging Market Facilities
8.2.4 The Vaccine Contract Manufacturing Business Model
8.3 Interview with Dr Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
8.3.1 Vaccine Contract Manufacturing Competition
8.3.2 Target Diseases For Vaccine Development
8.3.3 Challenge Stock Vaccines
8.3.4 Meridian's Vaccine Contract Manufacturing Revenue Stream Breakdown
8.3.5 The Changing Face of Large Pharma Drives Contract Manufacturing Growth
8.4 Interview with Dr Stefan Beyer, Managing Director, Vibalogics
8.4.1 The Benefits of Outsourcing Vaccine Manufacturing
8.4.2 The Challenges in Manufacturing Vaccines

9. Conclusion

9.1 Overview
9.2 Regulatory and Quality Standards Create High Barriers of Entry
9.3 Rich Pipeline for Therapeutic Vaccines
9.4 Emerging Markets will Show Stronger Growth
9.5 Technology Drives Changes in Manufacturing

List of Tables

Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD - Present
Table 3.1 Vaccine Development Pipeline Using Protein Sciences Corporation's BEVS Vaccine Technology, 2014
Table 3.2 Vaccine Development Pipeline Using Crucell's AdVac Technology, 2014
Table 3.3 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2014
Table 3.4 Companies Providing Disposable Biomanufacturing Platforms/Systems, 2014
Table 3.5 Some Leading Pre-Filled Syringe Vaccine Products, 2014
Table 3.6 Prominent Lyophilised Vaccines, 2014
Table 3.7 Examples of Serum-free Media for Vaccine Manufacturing, 2014
Table 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.2 The Global Vaccine Market: Revenue ($bn), Market Share by Submarket (%), 2012-2013
Table 4.3 The Global Vaccine Market by Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.4 The Paediatric Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.5 Selected Pipeline Vaccines in Paediatric Submarket, 2014
Table 4.6 The Adult Prophylactic Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024

Table 4.7 Selected Pipeline Vaccines in Adult Prophylactic Submarket, 2014
Table 4.8 The Influenza Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.9 Selected Pipeline Vaccines in Influenza Submarket, 2014
Table 4.10 The Therapeutic Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.11 Selected Pipeline Vaccines in Therapeutic Submarket, 2014
Table 5.1 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.2 The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m), Market Share (%), 2012-2013
Table 5.3 The Leading National Vaccine Contract Manufacturing Markets Forecasts: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.4 The US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.5 The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.6 The EU5 National Vaccine Contract Manufacturing Markets: Revenue ($m), Market Share (%) by Country, 2012-2013
Table 5.7 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.8 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.9 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.10 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.11 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.12 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.13 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.14 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.15 The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.16 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.1 Baxter BioPharma Solutions Capabilities, 2014

Table 6.2 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m), 2011-2012
Table 6.3 Catalent: Offerings and Services by Segment, 2014
Table 6.4 Catalent: Revenue($m), AGR (%), 2008-2012
Table 6.5 Catalent by Segment: Revenue($m), AGR (%), 2011-2012
Table 6.6 Charles River Laboratories: Services Provided by Segment, 2014
Table 6.7 Charles River Laboratories: Revenue ($bn), AGR (%), 2008-2012
Table 6.8 Charles River Laboratories: Pre-clinical Services Segment Revenue ($m), 3Q 2012-2013
Table 6.9 Charles River Laboratories: Revenue ($bn) by Segment, 2009-2012
Table 6.10 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2014
Table 6.11 IDT: Work Units in the Vaccine Production Line
Table 6.12 Lonza Custom Manufacturing: Revenue ($bn), AGR (%), 2010-2012
Table 6.13 Lonza: Revenue ($bn), Market Share (%) by Segment, 2012
Table 6.14 Meridian Bioscience: Revenue ($m), AGR (%), 2008-2013
Table 6.15 Meridian Bioscience: Revenue ($m), AGR (%) by Segment, 2010-2013
Table 6.16 Meridian Life Science: Revenue ($m), AGR (%) by Region, 2012-2013
Table 6.17 Sigma Aldrich: Revenue ($bn), AGR (%), 2010-2012
Table 6.18 Sigma Aldrich: Revenue ($bn) by Segment, 2010-2012
Table 6.19 SynCo's Capabilities, 2014
Table 6.20 Leading Vaccine Contract Manufacturing Organisations, 2014
Table 7.1 SWOT Analysis of the Vaccine Contract Manufacturing Market, 2012-2024

List of Figures

Figure 2.1 Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry, 2014
Figure 3.1 Influenza Vaccine Production Using a Cell-Based Manufacturing Method, 2014
Figure 3.2 Medicago's Product Pipeline, 2014
Figure 3.3 Novavax' Insect Egg-Based Vaccine Production Process, 2014
Figure 3.4 Novavax's Product Pipeline, 2014
Figure 3.5 Single-Use Bioreactors Market, 2012
Figure 3.6 Pre-filled Syringes Market: Drivers and Restraints, 2014-2024
Figure 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) 2012-2024
Figure 4.2 The Global Vaccine Market: Market Share by Submarket (%), 2013
Figure 4.3 The Paediatric Vaccine Market: Revenue ($bn), AGR (%), 2012-2024
Figure 4.4 The Adult Prophylactic Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
Figure 4.5 The Influenza Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
Figure 4.6 The Therapeutic Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
Figure 5.1 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.2 The Leading National Vaccine Contract Manufacturing Markets: Revenue (%) by region, 2013
Figure 5.3 The US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Figure 5.4 The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024

Figure 5.5 The EU5 Vaccine Contract Manufacturing Markets: Revenue (%) by Country, 2013
Figure 5.6 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.7 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.8 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.9 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.10 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.11 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.12 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.13 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.14 The Indian Vaccines Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.15 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Figure 6.1 Boehringer Ingelheim: Typical Contract Manufacturing Process, 2014
Figure 6.2 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m), 2011-2012
Figure 6.3 Catalent: Revenue ($m), AGR (%), 2008-2012

Figure 6.4 Catalent: Market Share (%) by Segment, 2012
Figure 6.5 Charles River Laboratories: Revenue ($bn), AGR (%), 2008-2012
Figure 6.6 Charles River Laboratories: Revenue ($bn), AGR (%), 3Q 2012-2013
Figure 6.7 Charles River Laboratories: Market Share (%) by Segment, 2012
Figure 6.8 Lonza Custom Manufacturing: Revenue ($bn), AGR (%), 2010-2012
Figure 6.9 Lonza: Market Share (%) by Segment, 2012
Figure 6.10 Meridian Bioscience: Revenue ($m), AGR (%), 2008-2013
Figure 6.11 Meridian Bioscience: Revenue ($m) by Segment, 2010-2013
Figure 6.12 Meridian Bioscience: Market Share (%) by Segment,2013
Figure 6.13 Meridian Life Science: Market Share by Region, 2013
Figure 6.14 Sigma Aldrich: Revenue ($bn), AGR (%), 2010-2013
Figure 6.15 Sigma Aldrich: Market Share (%) by Segment, 2012
Figure 6.16 Sigma Aldrich: Market Share (%) by Segment, 2013
Figure 7.1 Vaccines in the Pipeline, Phase 1-3
Figure 7.2 Drivers and Restraints for the Vaccine Contract Manufacturing Sector, 2014-2024
Figure 9.1 Vaccine & Vaccine Contract Manufacturing Market: AGR(%), 2012-2024
Figure 9.2 Therapeutic Vaccines in the Pipeline, Phase 1-3

Companies Listed

AAI Pharma Services Corp.
AbbVie
Accugenix
Activaris Biotech
Adamis Pharmaceuticals
Aduro Biotech
Advanced Bioscience Laboratories, Inc.
Advaxis
AFFiRis
Afrivax
Agenus
ALK- Abello

Alpha Biologics
AlphaVax
Althea Technologies, Inc.
Ambiopharm
Amgen
AmProtein
Antigen Express
Antigenics
Aptuit CTS
Argos Therapeutics
Artelis
AstraZeneca
ATMI
ATMI LifeSciences
AuRx
Avista Capital Partners
Batavia
Bavarian Nordic
Baxter
Baxter BioPharma Solutions
Bayer

Bayer Healthcare
Bayhill Therapeutics
Beijing Tiantan Biological Products
Bellicum Pharmaceuticals
Ben Venue Laboratories
Bend Research
Berna Biotech
Bharat Biotech International
Binnopharm
Biofabri
BioKangtai
Biological E. Serum Institute
Biomay
Biondvax
Bionor Pharma
BioReliance
BioSante Pharmaceuticals
Biovest International

Biovian
BN ImmunoTherapeutics
Boehringer Ingelheim
Bosch
Cadila Pharmceuticals
Cancer Advances
Cardinal Health
Catalent
Catalent (Shanghai) Clinical Trial Supplies
Catalent Pharma Solutions
CatScl
Celldex Therapeutics
Cellexus Limited
CEL-SCI
Celtic Pharma
Cerebricon
CG Therapeutics
Charles River Biopharmaceutical Services
Charles River Laboratories
Chengdu Institute of Biological Products
China National Biotech Corporation

Chiron B.V
Circassia
CMC Biologics
Cobra Biologics
Colby Pharmaceutical
Cook Pharmica
Corden Pharma
Covance
Crucell
CSL Biologicals
Cytos Biotechnology
Cytovance Biologics
Daiichi Sankyo
Dalian Hissen Bio-Pharm
DBV Technologies
Dendreon
DSM Biologics
Dynport Vaccine
EMD Serono
Emergent BioSolutions
Endocyte
Etubics
Eurogentec Biologics
FiberCell
Frazier Healthcare
Fujifilm Diosynth Biotechnologies
Galena
Gcon
GE Healthcare Life Sciences
GE Wave Biotech
GeneCure Biotechnologies
Genetic Immunity
Genocea Biosciences
GenPhar

GenVec
GeoVax
GlaxoSmithKline Biologicals
Gliknik
Globelmmune
Goodwin Biotechnology Inc.
Gradalis
Grand River Aseptic Manufacturing
GSK
Hawaii Biotech
Heat Biologics
Hospira
HTD Biosystems
iBio
IDT Biologika GmbH
immatics biotechnologies
Immune Response Biopharma
Immune Targeting Systems
Immunitor
ImmunoCellular Therapeutics
ImmunoFrontier
Immunomic Therapeutics
Immunotope
Immunovaccine
Immunovative Therapies
ImmunsanT
ImVisioN Therapeutics
Innogenetics Biologicals
Inovio Pharmaceuticals

Intercell Corporation
Inviragen
Invitrogen
Irvine Scientific
Janssen Alzheimer Immunotherapy
Japan Vaccine Co
Jennerex
JHP Pharmaceuticals
JN-International Medical
Johnson & Johnson
Jubilant HollisterStier
Kuhner
Leidos
LG Life Sciences
LigoCyte Pharmaceuticals
Liquidia Technologies
Lonza
MabVax Therapeutics
Medicago
MedImmune

Meisser Filtration
Memgen
Merck
Merck Serono
Meridian Life Science
Millipore
Mitsubishi Tanabe Pharma
MorphoSys
MP Biomedicals
NanoBio
Nanotherapeutics
Nascent Biologics
NewLink Genetics
Northwest Biotherapeutics
Novadigm Therapeutics
Novartis
Novartis Vaccines and Diagnostics
NovaRX
Novasep
Novavax
OncoPep
Oncothyreon
Opal Therapeutics
Opexa Therapeutics
Optimer Biotechnology
Orban Biotech
Organon Teknika Corporation
OSO Biopharmaceuticals Manufacturing

Pall Life Sciences
Pantec
Paragon Bioservices
Patheon
PaxVax
PBS Biotech
Penn Pharma
Pfizer (Wyeth Pharmaceuticals)
Pfrenex
PharmAthene
Philip Morris International
Piedmont Research Center
Pierre-Guérin Biolafitte
Pique Therapeutics
Polynoma
Prima Biomed
ProBioGen
Profectus BioSciences
Protein Sciences Corporation
Rame-Hart Sanovo
Refine Technology
Riemser Pharma GmbH
Roche
SAFC
Sanaria
Sanofi Pasteur
Sanofi Pasteur MSD

Sartorius Stedim Biotech
Selecta Biosciences
Selecta RUS
Shanghai Sunway Biotech
ShangPharma Corporation
Shantha Biotech
Sigma Aldrich
Soligenix
Stallergenes
Stemline Therapeutics
Sumagen
Sunovion Pharmaceuticals
Synco Bio Partners
Takeda
TapImmune
TD Vaccines
Theraclone Sciences
Thermo Fisher scientific
Thymon
Transgene
TVAX Biomedical
United Biomedical
Vaccine Technologies
Vaccinogen
Vaxart
VaxInnate
VaxOnco
Vibalogics
Vivalis

Waisman Biomanufacturing
Wave Biotech
Xcellerex
Xencor
ZellWerk
Zhangjiang Biotech & Pharmaceutical Base
Zhejiang Jiang Yuan Tang Biotechnology Corporation

Other Organisations Mentioned in This Report

Aaron Diamond AIDS Research Center
Aeras Global TB Vaccine Foundation
Agência Nacional de Vigilância Sanitária (ANVISA)
Centers for Disease Control and Prevention CDC (US)
Chinese State Food and Drug Administration (SFDA)
Defense Advanced Researched Projects Agency (DAPRA)
Emory University
European Medicines Agency (EMA)
Executive European Commission (European Union)
Health Canada
Hospital Clínic de Barcelona
Infectious Disease Research Institute (IDRI)

International AIDS Vaccine Initiative (IAVI)
Ministry of Industry and Trade (Russia)
Murdoch Childrens Research Institute
National Institute of Health (US)
PATH
Research Foundation for Microbial Diseases of Osaka University
The Department of Health and Human Services (HHS) (US)
The Drug Enforcement Administration (DEA) (US)
The Food and Drug Administration (FDA) (Korean)
The Food and Drug Administration (FDA) (US)
The National Institute of Allergy and Infectious Diseases (NIAID)
The U.S. Department of Health and Human Services Office of Biomedical Advanced Research and Development Authority (BARDA)
The United Nation Industrial Development Organisation (UNIDO)
US Naval Medical Research Center
Vaccine Manufacturers Associations (India)
World Health Organisation (WHO)

To order this report: Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024
http://www.reportlinker.com/p02148732/Vaccine-Manufacturing-Technology-and-Services-World-Market-Forecast-2014-2024.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.

  • NewsNewsMore>>

  • Will Ukraine Crisis Lead to New Cold War?

    Will Ukraine Crisis Lead to New Cold War?

    (WASHINGTON, D.C.) As the U.S. ratchets up economic sanctions against russia... some foreign policy experts suggest we are heading into a new "cold war."More >>
    (WASHINGTON, D.C.) As the U.S. ratchets up economic sanctions against russia... some foreign policy experts suggest we are heading into a new "cold war."
    More >>
  • Train Runs Over 2 Women Both Survive

    Train Runs Over 2 Women Both Survive

    The Indiana Rail Road Company has released video taken from the perspective of the conductor of a train as it ran over two women. More >>
    The Indiana Rail Road Company has released video taken from the perspective of the conductor of a train as it ran over two women. 
    More >>
  • New Treatment for Skin Cancer

    New Treatment for Skin Cancer

    (CINCINNATI, OH) There is a new type of treatment that those with skin cancer may not have heard about, it is commonly referred to as IL 2 or interleuken two, and to the right person it could make all the difference in survival.More >>
    (CINCINNATI, OH) There is a new type of treatment that those with skin cancer may not have heard about, it is commonly referred to as IL 2 or interleuken two, and to the right person it could make all the difference in survival.More >>
Powered by WorldNow

Siouxland News
100 Gold Circle
Dakota Dunes, SD 57049

Main Phone: 712-277-3554
Main Fax: 712-255-5250
Email: webmaster@siouxlandnews.com

Powered by WorldNow
All content © Copyright 2000 - 2009 WorldNow and Sinclair Communications, LLC. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.